Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson’s Disease

Ahuja, M.; Kaidery, N.A.; Dutta, D.; Attucks, O.C.; Kazakov, E.H.; Gazaryan, I.; Matsumoto, M.; Igarashi, K.; Sharma, S.M.; Thomas, B.

Авторы: Ahuja Manuj, Kaidery Navneet Ammal, Dutta Debashis, Attucks Otis C., Kazakov Eliot H., Gazaryan Irina, Matsumoto Mitsuyo, Igarashi Kazuhiko, Sharma Sudarshana M., Thomas Bobby
Журнал: ANTIOXIDANTS
Том: 11
Номер: 9
Год издания: 2022
Первая страница: 1780
Номер статьи: 1780
DOI: 10.3390/antiox11091780
Аннотация: Parkinson's disease (PD) is the second most common neurodegenerative movement disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Although a complex interplay of multiple environmental and genetic factors has been implicated, the etiology of neuronal death in PD remains unresolved. Various mechanisms of neuronal degeneration in PD have been proposed, including oxidative stress, mitochondrial dysfunction, neuroinflammation, α-synuclein proteostasis, disruption of calcium homeostasis, and other cell death pathways. While many drugs individually targeting these pathways have shown promise in preclinical PD models, this promise has not yet translated into neuroprotective therapies in human PD. This has consequently spurred efforts to identify alternative targets with multipronged therapeutic approaches. A promising therapeutic target that could modulate multiple etiological pathways involves drug-induced activation of a coordinated genetic program regulated by the transcription factor, nuclear factor E2-related factor 2 (Nrf2). Nrf2 regulates the transcription of over 250 genes, creating a multifaceted network that integrates cellular activities by expressing cytoprotective genes, promoting the resolution of inflammation, restoring redox and protein homeostasis, stimulating energy metabolism, and facilitating repair. However, FDA-approved electrophilic Nrf2 activators cause irreversible alkylation of cysteine residues in various cellular proteins resulting in side effects. We propose that the transcriptional repressor of BTB and CNC homology 1 (Bach1), which antagonizes Nrf2, could serve as a promising complementary target for the activation of both Nrf2-dependent and Nrf2-independent neuroprotective pathways. This review presents the current knowledge on the Nrf2/Bach1 signaling pathway, its role in various cellular processes, and the benefits of simultaneously inhibiting Bach1 and stabilizing Nrf2 using non-electrophilic small molecules as a novel therapeutic approach for PD.
Добавил в систему: Газарян Ирина Георгиевна

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ПсковГУ
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ПсковГУ

Harnessing the Therapeutic Potential of the Nrf2/Bach1 Signaling Pathway in Parkinson’s Diseaseстатья

Прикрепленные файлы